MANEHealthcare · Biotechnology

MANE Stock Forecast: Veradermics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026

$98

−4.24% on the day

The 7 Wall Street analysts covering Veradermics, Inc. hold a median 12-month price target of $167 — +69.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$4.3B

Ticker Nerd rank

2 / 100

Median analyst target

$167

Analysts covering

Revenue$0.0

Operating income−$29.7M

Net income−$27.2M

Free cash flow−$21.2M

Quarterly, 5 quarters to 31 Mar 2026 · latest quarter's figure shown

Total return, dividends reinvested

−9.0%

−10.1%

From high

−24.1%

From low

+165.9%

$37

$130

Range since 4 Feb 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

MANE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Veradermics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

2 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions

Size

Momentum

Issuance

Value

Growth

Accruals

Quality

Volatility

Revisions (53): Analysts have, on balance, been raising their forecasts.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MANE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MANE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 4 Feb 2026Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts

7 Buy0 Hold0 Sell

Low $135Median $167High $182

The green dot is the last close — the median target sits +69.6% from it.

Recent analyst actionsNewest first

Of the 13 most recent actions, 3 moved their price target up and 0 moved it down.

Date	Firm	Action	Rating	Target
16 July 2026	Citigroup	Maintains	Buy	$135 → $160
15 July 2026	B. Riley Securities	Initiates	Buy	$170
15 July 2026	Needham	Maintains	Buy	$136 → $164
7 July 2026	Jefferies	Maintains	Buy	—
7 July 2026	Jefferies	Maintains	Buy	$138 → $182
16 June 2026	LifeSci Capital	Initiates	Outperform	—
2 June 2026	Needham	Initiates	Buy	—
18 May 2026	Citigroup	Maintains	Buy	—
22 Apr 2026	Leerink Partners	Maintains	Outperform	—
2 Mar 2026	Cantor Fitzgerald	Initiates	Overweight	—
2 Mar 2026	Citigroup	Initiates	Buy	—
2 Mar 2026	Jefferies	Initiates	Buy	—
2 Mar 2026	Leerink Partners	Initiates	Outperform	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MANE appears on the weeks it earns a place.

Performance

MANE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

MANE vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MANE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Veradermics, Inc. (MANE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −51.6×
Price / sales: —
Price / book: 9.8×
EV / EBITDA: −49.7×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: 68.9%
Return on assets: −54.6%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Veradermics, Inc. (MANE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Veradermics, Inc. has a market value of $4.3B and an enterprise value of $3.5B.
Shares outstanding: 37.3M.
Trailing P/E: −51.6×; forward P/E: −38.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Veradermics, Inc. employs 37 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

MANE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
MANEVeradermics, Inc.	$4.3B	2
ELVNEnliven Therapeutics, Inc.	$4.3B	68
RLAYRelay Therapeutics, Inc.	$4.2B	72
CELCCelcuity, Inc.	$4.6B	30
VKTXViking Therapeutics, Inc.	$3.9B	35
DNLIDenali Therapeutics, Inc.	$3.9B	65
TNGXTango Therapeutics, Inc.	$3.9B	41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Veradermics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MANE news & analysis

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Business Wire · 11 Aug 2026positive

Veradermics reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate and clinical progress, including significant advancements in the development of VDPHL01 for female pattern hair loss.

Why it matters — The update signals forward momentum in the company's lead pipeline candidate for pattern hair loss, a key value driver for MANE.

FAQ

Frequently asked questions about MANE stock

What is the MANE stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Veradermics, Inc. have a median 12-month price target of $167, with estimates ranging from $135 to $182. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MANE stock a buy right now?

Of the 7 analysts covering Veradermics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Veradermics, Inc. 2 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MANE?

As at 22 Aug 2026, Veradermics, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (53 of 100).

Will MANE stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +69.6% from the last close, and Ticker Nerd's factor model ranks Veradermics, Inc. 2 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MANE stock forecast for 2030?

No analyst covering Veradermics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MANE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $135 to $182 over the next 12 months.

What does Veradermics, Inc. do?

Veradermics Inc. is a dermatologist-founded, late clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for prevalent aesthetic and dermatological conditions.

What is the latest news on MANE?

The most recent item we track (Business Wire, 11 Aug 2026): "Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress". Veradermics reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate and clinical progress, including significant advancements in the development of VDPHL01 for female pattern hair loss.

Company

About Veradermics, Inc.

Veradermics Inc. is a dermatologist-founded, late clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for prevalent aesthetic and dermatological conditions. Its primary focus centers on pattern hair loss, affecting approximately 50 million men and 30 million women in the United States, where current treatments suffer from high dissatisfaction due to slow results, side effects, and inconvenient administration. The company's lead candidate, VDPHL01, represents an oral, non-hormonal, extended-release formulation of minoxidil, originally a hypertension drug noted for hair growth side effects. This proprietary design aims to optimize hair restoration by maximizing plasma concentrations for follicular benefits while minimizing cardiac risks associated with immediate-release versions. Veradermics is advancing VDPHL01 through a registration-directed clinical program, including fully enrolled Phase 2/3 trials in males and ongoing Phase 3 trials in females, targeting FDA approval via a 505(b)(2) New Drug Application. Founded in 2019 and headquartered in New Haven, Connecticut, Veradermics addresses a $9 billion U.S. market opportunity in hair loss treatments, backed by a seasoned team with deep dermatology expertise.

CEO Dr. Reid Waldman M.D. · 37 employees · United States · https://www.veradermics.com